Frontline brentuximab vedotin in breast implant ‐associated anaplastic large‐cell lymphoma
We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is a rare peripheral T‐cell lymphoma. BIA‐ALCL presenting with a capsular mass show shorter survival despite implant removal followed by CHOP‐like chemotherapy. We present a patient with BIA‐ALCL successfully treated with frontline brentuximab vedotin.
Source: Clinical Case Reports - Category: General Medicine Authors: Juan Pablo Alderuccio, Amrita Desai, Monica M. Yepes, Jennifer R. Chapman, Francisco Vega, Izidore S. Lossos Tags: Case Report Source Type: research